Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.

Clin Chem 2010 Feb 10;56(2):165-71. Epub 2009 Dec 10.

Department of Chemistry, Purdue University, West Lafayette, IN, USA.

As a part of ongoing efforts of the NCI-FDA Interagency Oncology Task Force subcommittee on molecular diagnostics, members of the Clinical Proteomic Technology Assessment for Cancer program of the National Cancer Institute have submitted 2 protein-based multiplex assay descriptions to the Office of In Vitro Diagnostic Device Evaluation and Safety, US Food and Drug Administration. The objective was to evaluate the analytical measurement criteria and studies needed to validate protein-based multiplex assays. Each submission described a different protein-based platform: a multiplex immunoaffinity mass spectrometry platform for protein quantification, and an immunological array platform quantifying glycoprotein isoforms. Submissions provided a mutually beneficial way for members of the proteomics and regulatory communities to identify the analytical issues that the field should address when developing protein-based multiplex clinical assays.

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2009.140087DOI Listing
February 2010
49 Reads
19 Citations
7.911 Impact Factor

Publication Analysis

Top Keywords

protein-based multiplex
16
food drug
8
multiplex assays
8
drug administration
8
protein-based
5
device evaluation
4
submissions provided
4
diagnostic device
4
vitro diagnostic
4
evaluation safety
4
safety food
4
objective evaluate
4
isoforms submissions
4
administration objective
4
provided mutually
4
office vitro
4
multiplex assay
4
multiplex
4
submitted protein-based
4
protein quantification
4

Similar Publications